ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,404, issued on Sept. 30, was assigned to Halia Therapeutics Inc. (Lehi, Utah).
"Inhibitors of LRRK2 kinase" was invented by David James Bearss (Lehi, Utah), John Sai Keong Kauwe III (Lehi, Utah) and Alexis Henri Abel Mollard (Lehi, Utah).
According to the abstract* released by the U.S. Patent & Trademark Office: "Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I):or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R1a, R1b, R2, and L are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate...